About Us

Alzevita is an AI-powered, cloud-based brain MRI volumetry tool that automates hippocampal segmentation and generates quantitative volumetric reports. It is designed to support clinical and research workflows by improving speed, consistency, and confidence in neuroimaging analysis.

Alzevita uses AI-powered automated hippocampal segmentation based on deep-learning approaches and has been trained on large annotated neuroimaging datasets.

Detailed methodological documentation for publications or grant submissions is available upon request from Topia MedTech.

Alzevita is intended for use by:

• Radiologists and Neuroradiologists
• Neurologists
• Neuroscientists and Clinical Researchers

It supports both clinical practice and research applications.

Users can register directly via the Alzevita website. A guided walkthrough is available through the ‘Schedule a Meeting’ option for a personalised demonstration. Please also see our ‘How-to Videos’ on our website.

Yes. Live demonstrations are available upon request to explore Alzevita’s features and workflows before adoption. For live demonstration, click the link https://alzevita.com/Schedule-a-Meeting, then our experts will reach you for the demo.

For technical assistance or formal complaints, contact the support team at info@topiamedtech.com with details of the issue and, where applicable, the scan or case ID. Queries are acknowledged and responded to within two business days.

Alzevita operates on a credit-based system, where one credit corresponds to the analysis of one MRI scan.

Alzevita supports the following standard neuroimaging formats commonly used in clinical settings:

• DICOM
• NIfTI

This ensures compatibility with most radiology systems.

The workflow is simple and efficient:

1. Upload MRI scan
2. Automated AI-based segmentation is performed
3. Volumetric quantification is generated
4. Standardized report is exported for download

Currently, Alzevita focuses on hippocampal segmentation, a key biomarker in neurodegenerative diseases such as Alzheimer’s disease.

Volumetric reports are typically generated within minutes, depending on scan size and system load.

The Alzevita volumetric report provides a structured, quantitative assessment of hippocampal volume to support clinical interpretation.

Key sections of the report should be reviewed as follows^2,3,4:

• Hippocampal Volumes (Left, Right & Total): Absolute hippocampal volumes are reported in cubic centimetres (cm³) for the left hippocampus, right hippocampus, and the total hippocampal volume. These values represent the measured brain tissue volume derived from automated AI‑based segmentation.
• Normal Reference Range: Each volume measurement is accompanied by an age‑matched normative range derived from healthy individuals. Volumes falling below the lower bound of the reference range may indicate hippocampal atrophy, while values within range are considered typical for the patient’s following age.
• Normative Percentile: The percentile indicates how the patient’s hippocampal volume compares to a reference population. Lower percentile values reflect smaller hippocampal volumes relative to peers and may be clinically relevant when assessing neurodegenerative conditions.
• Hippocampal Asymmetry Index: The asymmetry index quantifies the relative difference between left and right hippocampal volumes. It is calculated as the difference between left and right volumes divided by the total hippocampal volume. Values outside the normal reference range may suggest asymmetric involvement and should be interpreted in conjunction with clinical findings.
• Visual Segmentation Output: The report includes visual overlays of the segmented hippocampi on the MRI images. These should be reviewed to confirm anatomical plausibility and identify any artefacts or boundary inconsistencies that may affect quantitative results.
• Measurement Variability Note: The report specifies the expected measurement variability (± cm³) due to segmentation differences and image quality. This is particularly important when comparing serial scans during longitudinal follow‑up.

Overall, the volumetric report is intended to provide objective, standardised quantitative data that supports clinical assessment. All findings should be interpreted alongside the patient’s clinical symptoms, cognitive assessments, and other imaging findings by a qualified healthcare professional. For further use, please refer to the Instructions For Use (IFU) document.

Overall, the volumetric report is intended to provide objective, standardised quantitative data that supports clinical assessment. All findings should be interpreted alongside the patient’s clinical symptoms, cognitive assessments, and other imaging findings by a qualified healthcare professional.

For further use, please refer to the Instructions For Use (IFU) document.

References

• De Francesco, S., Galluzzi, S., Vanacore, N., Festari, C., Paolo M. Rossini, Stefano F. Cappa, Giovanni B. Frisoni and Andrea Redolfi (2021) ‘Norms for automatic estimation of hippocampal atrophy and a step forward for applicability to the Italian population’, Frontiers in Neuroscience, 15, p. 656808. Available at: https://doi.org/10.3389/fnins.2021.656808.
• Sarica, A., Vasta, R., Novellino, F., Vaccaro, M.G., Cerasa, A., Quattrone, A. and Alzheimer's Disease Neuroimaging Initiative (2018) ‘MRI asymmetry index of hippocampal subfields increases through the continuum from mild cognitive impairment to Alzheimer’s disease’, Frontiers in Neuroscience, 12, p. 576.
• Deangeli, D., Iarussi, F., Külsgaard, H., Braggio, D., Princich, J.P., Bendersky, M., Iarussi, E., Larrabide, I. and Orlando, J.I. (2023) ‘NORHA: A normal hippocampal asymmetry deviation index based on one-class novelty detection and 3D shape features’, Brain Topography, 36(5), pp. 644–660. Available at: https://doi.org/10.1007/s10548-023-00985-6.

Alzevita’s hippocampal segmentation performance has been analytically validated against expert manual annotations using an independent dataset comprising of 298 MRI scans. In validation testing, the algorithm achieved an average Dice similarity score of 0.86 and a Hausdorff distance of 1.51 mm, demonstrating high geometric agreement with expert consensus segmentations and minimal boundary error.

Quantitative volume comparison showed a strong correlation with expert manual measurements (r = 0.93) and a relative volume difference of 10.64%, well below the predefined acceptance threshold for longitudinal monitoring. Bland–Altman analysis indicated minimal systematic bias, with a mean total hippocampal volume difference of 0.485 cm³.

Performance remained consistently high across clinical subgroups (healthy controls, MCI, and Alzheimer’s disease), MRI field strengths (1.5T and 3T), slice thicknesses, genders, and geographic regions, supporting the robustness and reproducibility of the algorithm.

As with all quantitative imaging tools, Alzevita is intended to support clinical decision‑making, and results should always be reviewed and interpreted in the context of the full clinical picture by a qualified healthcare professional.

As with all quantitative tools, results should be interpreted in the context of the full clinical picture by a qualified healthcare professional.

No. Alzevita is a clinical decision-support tool, and does not replace radiologists or clinicians. Final clinical interpretation and diagnosis must always be made by qualified healthcare professionals.

Manual hippocampal segmentation is highly operator dependent. Alzevita significantly reduces this variability by applying the same AI model consistently across all scans, operators, and time points, improving objectivity and reliability.

Alzevita operates on a credit-based system, where one credit corresponds to the analysis of one MRI scan.

Alzevita provides quantitative hippocampal volumetry, a well‑established biomarker in Alzheimer’s disease and Mild Cognitive Impairment (MCI). When interpreted alongside clinical symptoms, cognitive assessments, and other imaging findings, this supports earlier clinical assessment and more informed care planning.

Yes. Alzevita is designed to support consistent longitudinal analysis, enabling reliable monitoring of disease progression and response to therapy across multiple time points.

Yes. Its reproducibility, consistency, and standardised outputs make it suitable for:

• Neuroimaging research
• Cohort studies
• Drug and clinical trials
• Biomarker development

Yes. Standardised reports and volumetric data can be exported and incorporated into statistical analysis pipelines and research documentation.

Currently, Alzevita operates as a cloud-based system. PACS integration is under development. Future options may include cloud-based workflows, PACS-integrated transfer and storage, and report access via PACS.

Users should report the case to customer support with the relevant case ID and a description of the concern. The clinical or technical team will review the issue and respond promptly. Reprocessing the scan may be performed where appropriate.

• US FDA 510(k) cleared
• Licensed under CDSCO (India) Medical Device Rules

All MRI data is transmitted and stored using industry‑standard encryption. Alzevita is developed in alignment with applicable data protection regulations, including HIPAA and GDPR principles. Patient data is never used for commercial purposes without explicit consent.